Medical - Healthcare Information Services
Compare Stocks
5 / 10Stock Comparison
HCTI vs DBVT vs HIMS vs ALKS vs INVA
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Medical - Equipment & Services
Biotechnology
Biotechnology
HCTI vs DBVT vs HIMS vs ALKS vs INVA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Biotechnology | Medical - Equipment & Services | Biotechnology | Biotechnology |
| Market Cap | $49K | $1712.35T | $6.63B | $5.90B | $1.93B |
| Revenue (TTM) | $13M | $0.00 | $2.35B | $1.56B | $424M |
| Net Income (TTM) | $-6M | $-168M | $128M | $153M | $504M |
| Gross Margin | 13.1% | — | 69.7% | 65.4% | 76.2% |
| Operating Margin | -45.2% | — | 4.6% | 12.3% | 14.8% |
| Forward P/E | — | — | 51.5x | 24.8x | 11.9x |
| Total Debt | $3M | $22M | $1.12B | $70M | $269M |
| Cash & Equiv. | $20K | $194M | $229M | $1.12B | $551M |
HCTI vs DBVT vs HIMS vs ALKS vs INVA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Oct 21 | May 26 | Return |
|---|---|---|---|
| Healthcare Triangle… (HCTI) | 100 | 0.0 | -100.0% |
| DBV Technologies S.… (DBVT) | 100 | 66.0 | -34.0% |
| Hims & Hers Health,… (HIMS) | 100 | 329.0 | +229.0% |
| Alkermes plc (ALKS) | 100 | 116.9 | +16.9% |
| Innoviva, Inc. (INVA) | 100 | 130.7 | +30.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HCTI vs DBVT vs HIMS vs ALKS vs INVA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
HCTI lags the leaders in this set but could rank higher in a more targeted comparison.
DBVT is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 0 yrs, beta 1.26
- +110.4% vs HCTI's -99.9%
HIMS ranks third and is worth considering specifically for growth exposure and long-term compounding.
- Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
- 161.9% 10Y total return vs INVA's 94.9%
- 59.0% revenue growth vs DBVT's -100.0%
Among these 5 stocks, ALKS doesn't own a clear edge in any measured category.
INVA carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 0.13, Low D/E 22.9%, current ratio 14.64x
- Beta 0.13, current ratio 14.64x
- Lower P/E (11.9x vs 24.8x)
- 118.9% margin vs HCTI's -48.9%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 59.0% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (11.9x vs 24.8x) | |
| Quality / Margins | 118.9% margin vs HCTI's -48.9% | |
| Stability / Safety | Beta 0.13 vs HCTI's 3.07 | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +110.4% vs HCTI's -99.9% | |
| Efficiency (ROA) | 32.4% ROA vs DBVT's -89.0% |
HCTI vs DBVT vs HIMS vs ALKS vs INVA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
HCTI vs DBVT vs HIMS vs ALKS vs INVA — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
INVA leads in 2 of 6 categories
ALKS leads 1 • HIMS leads 1 • HCTI leads 0 • DBVT leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
INVA leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HIMS and DBVT operate at a comparable scale, with $2.3B and $0 in trailing revenue. INVA is the more profitable business, keeping 118.9% of every revenue dollar as net income compared to HCTI's -48.9%. On growth, HCTI holds the edge at +44.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $13M | $0 | $2.3B | $1.6B | $424M |
| EBITDAEarnings before interest/tax | -$6M | -$112M | $164M | $212M | $86M |
| Net IncomeAfter-tax profit | -$6M | -$168M | $128M | $153M | $504M |
| Free Cash FlowCash after capex | -$12M | -$151M | $73M | $392M | $181M |
| Gross MarginGross profit ÷ Revenue | +13.1% | — | +69.7% | +65.4% | +76.2% |
| Operating MarginEBIT ÷ Revenue | -45.2% | — | +4.6% | +12.3% | +14.8% |
| Net MarginNet income ÷ Revenue | -48.9% | — | +5.5% | +9.8% | +118.9% |
| FCF MarginFCF ÷ Revenue | -94.7% | — | +3.1% | +25.1% | +42.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +44.6% | — | +28.4% | +28.2% | +10.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -63.8% | +91.5% | -27.3% | -4.1% | +4.0% |
Valuation Metrics
INVA leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 6.9x trailing earnings, INVA trades at a 86% valuation discount to HIMS's 50.3x P/E. On an enterprise value basis, INVA's 8.1x EV/EBITDA is more attractive than HIMS's 42.7x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $49,177 | $1712.35T | $6.6B | $5.9B | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $3M | $1712.35T | $7.5B | $4.9B | $1.7B |
| Trailing P/EPrice ÷ TTM EPS | -0.01x | -0.76x | 50.32x | 24.76x | 6.91x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 51.51x | — | 11.91x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 0.67x |
| EV / EBITDAEnterprise value multiple | — | — | 42.68x | 17.25x | 8.10x |
| Price / SalesMarket cap ÷ Revenue | 0.00x | — | 2.82x | 4.00x | 4.55x |
| Price / BookPrice ÷ Book value/share | — | 0.66x | 12.25x | 3.28x | 1.65x |
| Price / FCFMarket cap ÷ FCF | — | — | 89.61x | 12.28x | 9.88x |
Profitability & Efficiency
ALKS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
INVA delivers a 46.5% return on equity — every $100 of shareholder capital generates $46 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs HCTI's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -112.9% | -130.2% | +23.7% | +8.8% | +46.5% |
| ROA (TTM)Return on assets | -60.0% | -89.0% | +6.0% | +5.4% | +32.4% |
| ROICReturn on invested capital | -6.3% | — | +10.7% | +18.9% | +14.2% |
| ROCEReturn on capital employed | — | -145.7% | +10.9% | +14.2% | +12.4% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 4 | 7 | 5 |
| Debt / EquityFinancial leverage | — | 0.13x | 2.07x | 0.04x | 0.23x |
| Net DebtTotal debt minus cash | $3M | -$172M | $892M | -$1.0B | -$282M |
| Cash & Equiv.Liquid assets | $20,000 | $194M | $229M | $1.1B | $551M |
| Total DebtShort + long-term debt | $3M | $22M | $1.1B | $70M | $269M |
| Interest CoverageEBIT ÷ Interest expense | -3.79x | -189.82x | — | 32.30x | 63.45x |
Total Returns (Dividends Reinvested)
HIMS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $0 for HCTI. Over the past 12 months, DBVT leads with a +110.4% total return vs HCTI's -99.9%. The 3-year compound annual growth rate (CAGR) favors HIMS at 29.4% vs HCTI's -96.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -93.7% | +4.9% | -23.2% | +25.3% | +14.7% |
| 1-Year ReturnPast 12 months | -99.9% | +110.4% | -51.0% | +16.5% | +21.7% |
| 3-Year ReturnCumulative with dividends | -100.0% | +19.7% | +116.6% | +14.5% | +95.2% |
| 5-Year ReturnCumulative with dividends | -100.0% | -69.1% | +137.6% | +60.9% | +94.4% |
| 10-Year ReturnCumulative with dividends | -100.0% | -87.0% | +161.9% | -11.0% | +94.9% |
| CAGR (3Y)Annualised 3-year return | -96.0% | +6.2% | +29.4% | +4.6% | +25.0% |
Risk & Volatility
Evenly matched — ALKS and INVA each lead in 1 of 2 comparable metrics.
Risk & Volatility
INVA is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than HCTI's 3.07 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs HCTI's 0.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.07x | 1.26x | 2.40x | 1.06x | 0.13x |
| 52-Week HighHighest price in past year | $7410.00 | $26.18 | $70.43 | $36.60 | $25.15 |
| 52-Week LowLowest price in past year | $0.29 | $7.53 | $13.74 | $25.17 | $16.52 |
| % of 52W HighCurrent price vs 52-week peak | +0.0% | +76.3% | +36.4% | +96.7% | +90.7% |
| RSI (14)Momentum oscillator 0–100 | 36.7 | 48.1 | 54.5 | 60.2 | 39.9 |
| Avg Volume (50D)Average daily shares traded | 572K | 252K | 34.9M | 2.3M | 621K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: DBVT as "Buy", HIMS as "Hold", ALKS as "Buy", INVA as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 15.6% for HIMS (target: $30).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | — | $46.33 | $29.67 | $44.00 | $37.67 |
| # AnalystsCovering analysts | — | 15 | 19 | 28 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | — | 0 | 0 |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +1.4% | +0.5% | +0.2% |
INVA leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). ALKS leads in 1 (Profitability & Efficiency). 1 tied.
HCTI vs DBVT vs HIMS vs ALKS vs INVA: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is HCTI or DBVT or HIMS or ALKS or INVA a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -64. 8% for Healthcare Triangle, Inc. (HCTI). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — HCTI or DBVT or HIMS or ALKS or INVA?
On trailing P/E, Innoviva, Inc.
(INVA) is the cheapest at 6. 9x versus Hims & Hers Health, Inc. at 50. 3x. On forward P/E, Innoviva, Inc. is actually cheaper at 11. 9x.
03Which is the better long-term investment — HCTI or DBVT or HIMS or ALKS or INVA?
Over the past 5 years, Hims & Hers Health, Inc.
(HIMS) delivered a total return of +137. 6%, compared to -100. 0% for Healthcare Triangle, Inc. (HCTI). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus HCTI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — HCTI or DBVT or HIMS or ALKS or INVA?
By beta (market sensitivity over 5 years), Innoviva, Inc.
(INVA) is the lower-risk stock at 0. 13β versus Healthcare Triangle, Inc. 's 3. 07β — meaning HCTI is approximately 2337% more volatile than INVA relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — HCTI or DBVT or HIMS or ALKS or INVA?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus -64. 8% for Healthcare Triangle, Inc. (HCTI). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — HCTI or DBVT or HIMS or ALKS or INVA?
Innoviva, Inc.
(INVA) is the more profitable company, earning 63. 8% net margin versus -51. 0% for Healthcare Triangle, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -40. 6% for HCTI. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is HCTI or DBVT or HIMS or ALKS or INVA more undervalued right now?
On forward earnings alone, Innoviva, Inc.
(INVA) trades at 11. 9x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 39. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — HCTI or DBVT or HIMS or ALKS or INVA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is HCTI or DBVT or HIMS or ALKS or INVA better for a retirement portfolio?
For long-horizon retirement investors, Innoviva, Inc.
(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). Healthcare Triangle, Inc. (HCTI) carries a higher beta of 3. 07 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +94. 9%, HCTI: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between HCTI and DBVT and HIMS and ALKS and INVA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: HCTI is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; HIMS is a small-cap high-growth stock; ALKS is a small-cap quality compounder stock; INVA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.